Short answer
CARLSMED, INC. (CARL) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
CARLSMED, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $18.9M, up 57% year-over-year, confirming accelerating adoption of aprevo spine procedures
- Gross margin expanded to 76.8% from 73.4%, supporting stronger operating leverage as production scales
- Full-year 2026 revenue guidance raised to $74M–$78M from $72M–$77M, exceeding 50% growth at midpoint
- Losses widened: net loss $10.5M and adjusted EBITDA loss $8.6M, despite revenue and margin gains
- CMS reimbursement takes effect October 1, 2026, potentially improving Medicare access and demand for lumbar aprevo procedures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CARLSMED, INC. 8-K filings
Get the next CARL 8-K as it lands
Follow CARL for push alerts, or ask the research agent what this filing means.